Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei

被引:27
|
作者
Kusamura, Shigeki [1 ]
Hutanu, Ionut [2 ]
Baratti, Dario [1 ]
Deraco, Marcello [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumouri Milano, Dept Surg, Peritoneal Surface Malignancy Program, I-20133 Milan, Italy
[2] Univ Med & Pharm Gr T Popa, Iasi, Romania
关键词
cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; circulating Tumor markers; prognosis; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; APPENDICEAL ORIGIN; CARCINOEMBRYONIC ANTIGEN; SURFACE MALIGNANCY; CARCINOMATOSIS; SURGERY; CAPECITABINE; PERFORMANCE; MORBIDITY; TOXICITY;
D O I
10.1002/jso.23329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Incomplete cytoreduction (IC) is one of the main prognostic factor in pseudomyxoma peritonei (PMP). We evaluated the ability of preoperative Ca125, CEA, and Ca19-9 to predict IC and prognosis in PMP. Methods One hundred fifty-six cases elected candidate to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 1996 to 2011 were included in the study. We assessed the: (1) optimal cut-off values for circulating Tumor markers (CTM) in predicting IC (residual disease >2.5mm) using receiver-operating characteristics (ROC); (2) discriminant power of CTM and risk prediction models for IC by calculating the area under ROC curve (AUC-ROC); (3) prognostic factors using Cox proportional-hazard model. Results Optimal cut-offs were 125U/ml for Ca125, 18ng/ml for CEA, and 89U/ml for Ca19-9. The AUCs-ROC were 0.76, 0.68, and 0.69 for Ca125, CEA, and Ca19-9, respectively. The addition of CTM to risk prediction model that considered preoperative clinicopathological factors increased marginally the AUC-ROC (0.80-0.84). Ca125>125U/ml, Ca19-9>89U/ml independently affected overall survival. Conclusions Preoperative CTMs were reasonable but not perfect discriminators of IC. Moreover, Ca125 and Ca19-9, using new cut-off values, were proven to be new strong prognostic factors that overcome the value of disease extension and histological subtype. J. Surg. Oncol. 2013;108:1-8. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 36 条
  • [1] Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei
    Lopes, Andre
    de Mello, Evandro Sobroza
    Mendoza Lopez, Rossana Veronica
    Leonardi, Paulo Cesar
    Ribeiro Jr, Ulysses
    JOURNAL OF SURGICAL RESEARCH, 2022, 274 : 68 - 76
  • [2] Nomogram to Predict Incomplete Cytoreduction for Pseudomyxoma Peritonei
    Bai, Mingjian
    Wang, Shilong
    Liang, Guowei
    Cai, Ying
    Lu, Yiyan
    Hou, Nianzong
    Ma, Ruiqing
    Xu, Hongbin
    Zhang, Man
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (02) : 885 - 892
  • [3] Nomogram to Predict Incomplete Cytoreduction for Pseudomyxoma Peritonei
    Mingjian Bai
    Shilong Wang
    Guowei Liang
    Ying Cai
    Yiyan Lu
    Nianzong Hou
    Ruiqing Ma
    Hongbin Xu
    Man Zhang
    Annals of Surgical Oncology, 2022, 29 : 885 - 892
  • [4] ASO Author Reflections: Incomplete Cytoreduction Prediction Model for Pseudomyxoma Peritonei
    Bai, Mingjian
    Xu, Hongbin
    Zhang, Man
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 3) : 574 - 574
  • [5] ASO Author Reflections: Incomplete Cytoreduction Prediction Model for Pseudomyxoma Peritonei
    Mingjian Bai
    Hongbin Xu
    Man Zhang
    Annals of Surgical Oncology, 2022, 29 : 574 - 574
  • [6] Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei
    Foster, J. M.
    Grotz, T. E.
    Turaga, K. K.
    Gatalica, Z.
    Sharma, P.
    Loggie, B. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Circulating Tumor Cells and Circulating Tumor DNA in Patients with PseudoMyxoma Peritonei
    Dazza, Marie
    Toure, Emmanuel
    Blanchard, France
    Paresy, Marianne
    Sarafan-Vasseur, Nasrin
    Sabourin, Jean-Christophe
    LABORATORY INVESTIGATION, 2016, 96 : 168A - 169A
  • [8] Circulating Tumor Cells and Circulating Tumor DNA in Patients with PseudoMyxoma Peritonei
    Dazza, Marie
    Toure, Emmanuel
    Blanchard, France
    Paresy, Marianne
    Sarafan-Vasseur, Nasrin
    Sabourin, Jean-Christophe
    MODERN PATHOLOGY, 2016, 29 : 168A - 169A
  • [9] Recurrence of pseudomyxoma peritonei after cytoreduction and hyperthermic intraperitoneal chemotherapy: Location, treatment, and outcome
    Smeenk, R
    Verwaal, VJ
    Zoetmulder, FA
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 25 - 25
  • [10] Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
    Baratti, Dario
    Kusamura, Shigeki
    Nonaka, Daisuke
    Cabras, Antonello Domenico
    Laterza, Barbara
    Deraco, Marcello
    ANNALS OF SURGERY, 2009, 249 (02) : 243 - 249